Revolution Medicines Introduces Breakthrough Elironrasib for the Treatment of KRAS G12C-Mutated Non-Small Cell Lung Cancer
Revolution Medicines has introduced elironrasib as the first and only investigational therapy to receive FDA Breakthrough Therapy designation for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Elironrasib is a selective and covalent RAS(ON) G12C inhibitor designed to directly target the active, oncogenic form of the RAS G12C protein. The therapy aims to block tumour growth in cancers driven by KRAS mutations, which are known to occur in a significant portion of NSCLC cases.
KRAS G12C mutations account for approximately 12% of NSCLC cases, and currently, there are no fully approved RAS-targeted therapies available for this patient group. The disease often presents in an advanced stage, with limited treatment options after standard chemotherapy and immunotherapy.
The FDA’s Breakthrough Therapy designation recognises the potential of elironrasib to address this high unmet medical need. The designation is supported by results from the Phase 1 RMC-6291-001 trial, which showed encouraging antitumour activity, a favourable safety profile, and meaningful clinical responses.
Non-small cell lung cancer represents 80% to 85% of all lung cancer diagnoses. Despite advances in treatment, it remains a leading cause of cancer-related deaths worldwide, largely due to late detection and limited efficacy of current therapies in advanced stages.
Elironrasib is the first and only investigational therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of KRAS G12C-mutated non-small cell lung cancer.
